2026 / 05

DOI: 10.24075/brsmu.2026.051
Copyright: © 2026 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Long-term outcomes of the trial of the RAS-GTPase inhibitor (“Ing-Ras”) efficacy in advanced gastric and colon tumors

Kulinich TM , Kudinova EA , Goncharov SV , Kukoleva EA , Puchkov IA , Chaptykov AA , Dovgan FN , Goncharova OI , Bozhenko VK
About authors

Russian Scientific Center for Roentgenoradiology, Moscow, Russia

Correspondence should be addressed: Tatiana M. Kulinich
Profsoyuznaya, 86, Moscow, 117997, Russia; ur.liam@larbos

About paper

Funding: the study was conducted with financial support from the Ministry of Health of the Russian Federation, the State Task project No. 1023021500033-4-3.2.21;3.1.5.

Author contribution: Kulinich TM — research design, analysis of results, manuscript writing; Kudinova EA — clinical trial plan and procedure, assessment of results; Goncharov SV, Kukoleva EA, Chaptykov AA — implementation of main clinical trial procedures; Puchkov IA — monitoring the trial progress, interpretation of results, manuscript writing; Dovgan FN — analysis of results, manuscript writing; Goncharova OI — contribution to the clinical trial, assessment of results; Bozhenko VK — developing the research design, statistical analysis and assessment of results, manuscript writing.

Compliance with ethical standards: the study was approved by the Ethics Council of the Ministry of Health of the Russian Federation (protocol No. 325 dated 17 January, 2023), initial approval of the Ministry of Health of the Russian Federation to conduct the clinical trial No. 177 dated 30 March, 2023 was obtained. The study was approved by the Ethics Committee of the Russian Scientific Center of Roentgenoradiology (protocol No. 4 dated April 28, 2023). All patients submitted the informed consent to take part in the study.

Received: 2026-08-18 Accepted: 2026-09-10 Published online: 2026-09-20
|

Peritoneal carcinomatosis in colorectal and gastric cancer is associated with the extremely poor prognosis and the limited standard therapy efficacy, which suggests the need to develop new targeted drugs. The study aimed to assess the long-term outcomes of the efficacy of the RAS-GTPase peptide inhibitor (“Ing-Ras”) intraperitoneally administered by the PIPAC method to patients with stage III–IV gastric and colorectal tumors. A total of 38 patients (21 with colorectal cancer (CRC), 17 with gastric cancer (GC), including with peritoneal carcinomatosis) were included in the prospective open-label nonrandomized multicenter phase I/IIa trial. The long-term outcomes were assessed after 30 months of follow-up. A significant increase in the overall survival parameters was reported for both disease entities: the one- and two-year overall survival was 95.24 and 80.95% for CRC (historical control: 65–85% and 50–65%), 76.47 and 47.06%, respectively, for GC vs. 40–60% and 20–30%; progression and recurrence rates decreased significantly. Thus, the use of “Ing-Ras” makes it possible to increase the survival rate and reduce the recurrence rate relative to the historical control, which justifies conducting phase III trials.

Keywords: colorectal cancer, gastric cancer, peritoneal carcinomatosis, KRAS, peptide inhibitor of RAS-GTPase, “Ing-Ras”, PIPAC

КОММЕНТАРИИ (0)